涉及肾脏OCT2/MATE转运体的药物相互作用：临床风险评估可能需要基于内源性生物标志物的方法。 - Suppr

Suppr

超能文献

Drug-Drug Interactions Involving Renal OCT2/MATE Transporters: Clinical Risk Assessment May Require Endogenous Biomarker-Informed Approach.

作者信息

Mathialagan Sumathy, Feng Bo, Rodrigues A David, Varma Manthena V S

机构信息

Pharmacokinetics, Dynamics, and Metabolism, Medicine Design, Worldwide R&D, Pfizer Inc., Groton, Connecticut, USA.

出版信息

Clin Pharmacol Ther. 2021 Oct;110(4):855-859. doi: 10.1002/cpt.2089. Epub 2020 Nov 13.

DOI:10.1002/cpt.2089

PMID:33186483

Abstract

摘要

相似文献

Drug-Drug Interactions Involving Renal OCT2/MATE Transporters: Clinical Risk Assessment May Require Endogenous Biomarker-Informed Approach.涉及肾脏OCT2/MATE转运体的药物相互作用：临床风险评估可能需要基于内源性生物标志物的方法。

Clin Pharmacol Ther. 2021 Oct;110(4):855-859. doi: 10.1002/cpt.2089. Epub 2020 Nov 13.

N(1)-methylnicotinamide as an endogenous probe for drug interactions by renal cation transporters: studies on the metformin-trimethoprim interaction.N(1)-甲基烟酰胺作为肾脏阳离子转运体药物相互作用的内源性探针：二甲双胍-甲氧苄啶相互作用的研究

Eur J Clin Pharmacol. 2015 Jan;71(1):85-94. doi: 10.1007/s00228-014-1770-2. Epub 2014 Oct 22.

Lack of Drug-Drug Interaction Between Cimetidine, a Renal Transporter Inhibitor, and Imeglimin, a Novel Oral Antidiabetic Drug, in Healthy Volunteers.肾转运体抑制剂西咪替丁与新型口服抗糖尿病药物依美格列明在健康志愿者中不存在药物相互作用。

Eur J Drug Metab Pharmacokinet. 2020 Dec;45(6):725-733. doi: 10.1007/s13318-020-00642-4.

Tucatinib Inhibits Renal Transporters OCT2 and MATE Without Impacting Renal Function in Healthy Subjects.图卡替尼抑制健康受试者的肾脏转运体 OCT2 和 MATE，而不影响肾功能。

J Clin Pharmacol. 2021 Apr;61(4):461-471. doi: 10.1002/jcph.1750. Epub 2020 Sep 28.

Importance of OCT2 and MATE1 for the Cimetidine-Metformin Interaction: Insights from Investigations of Polarized Transport in Single- And Double-Transfected MDCK Cells with a Focus on Perpetrator Disposition.OCT2 和 MATE1 对西咪替丁-二甲双胍相互作用的重要性：从单转染和双转染 MDCK 细胞中极性转运的研究中获得的见解，重点关注引发剂处置。

Mol Pharm. 2018 Aug 6;15(8):3425-3433. doi: 10.1021/acs.molpharmaceut.8b00416. Epub 2018 Jul 19.

A drug-drug interaction study to evaluate the impact of peficitinib on OCT1- and MATE1-mediated transport of metformin in healthy volunteers.一项药物相互作用研究，评估培非替尼对健康志愿者中 OCT1 和 MATE1 介导的二甲双胍转运的影响。

Eur J Clin Pharmacol. 2020 Aug;76(8):1135-1141. doi: 10.1007/s00228-020-02876-2. Epub 2020 May 16.

Pregnancy Increases the Renal Secretion of N-methylnicotinamide, an Endogenous Probe for Renal Cation Transporters, in Patients Prescribed Metformin.对于服用二甲双胍的患者，妊娠会增加肾阳离子转运体的内源性探针N-甲基烟酰胺的肾脏分泌。

Drug Metab Dispos. 2017 Mar;45(3):325-329. doi: 10.1124/dmd.116.073841. Epub 2017 Jan 9.

Fampridine is a Substrate and Inhibitor of Human OCT2, but not of Human MATE1, or MATE2K.氨苯砜是人类 OCT2 的底物和抑制剂，但不是人类 MATE1 或 MATE2K 的底物和抑制剂。

Pharm Res. 2018 Jun 18;35(8):159. doi: 10.1007/s11095-018-2445-y.

Evaluation of Renal Transporter Inhibition Using Creatinine as a Substrate In Vitro to Assess the Clinical Risk of Elevated Serum Creatinine.采用肌酐作为底物评估肾脏转运体抑制作用的体外试验以评估血清肌酐升高的临床风险。

J Pharm Sci. 2017 Sep;106(9):2535-2541. doi: 10.1016/j.xphs.2017.04.009. Epub 2017 Apr 14.

Inhibition of OCT2, MATE1 and MATE2-K as a possible mechanism of drug interaction between pazopanib and cisplatin.OCT2、MATE1 和 MATE2-K 的抑制可能是帕唑帕尼与顺铂药物相互作用的机制之一。

Pharmacol Res. 2016 Aug;110:89-95. doi: 10.1016/j.phrs.2016.05.012. Epub 2016 May 10.

引用本文的文献

Drug Interaction PBPK Modeling: Review of the Literature Exposes the Need for Increased Verification of Model Inputs and Outputs as Part of Credibility Assessment.药物相互作用的生理药代动力学（PBPK）建模：文献综述揭示，作为可信度评估的一部分，需要加强对模型输入和输出的验证。

Clin Transl Sci. 2025 Jul;18(7):e70299. doi: 10.1111/cts.70299.

Is 1-Methylnicotinamide a Good Organic Cation Transporter 2 (OCT2) Biomarker?1-甲基烟酰胺是一种良好的有机阳离子转运体2（OCT2）生物标志物吗？

Metabolites. 2025 Jan 29;15(2):80. doi: 10.3390/metabo15020080.

A Joint Pharmacometric Model of Iohexol and Creatinine Administered through a Meat Meal to Assess GFR and Renal OCT2/MATE Activity.通过肉餐给药的碘海醇和肌酐联合药代动力学模型，用于评估肾小球滤过率和肾脏有机阳离子转运体2/多药及毒素外排家族成员活性

Clin Pharmacol Ther. 2025 Aug;118(2):510-519. doi: 10.1002/cpt.3612. Epub 2025 Feb 25.

Endogenous plasma riboflavin is not a viable BCRP biomarker in human.内源性血浆核黄素并非人类可行的乳腺癌耐药蛋白生物标志物。

Clin Transl Sci. 2024 Dec;17(12):e70109. doi: 10.1111/cts.70109.

Prediction of Inhibitory Activity against the MATE1 Transporter via Combined Fingerprint- and Physics-Based Machine Learning Models.基于指纹和物理的机器学习模型联合预测对 MATE1 转运蛋白的抑制活性。

J Chem Inf Model. 2024 Sep 23;64(18):7068-7076. doi: 10.1021/acs.jcim.4c00921. Epub 2024 Sep 10.

Expanding Role of Endogenous Biomarkers for Assessment of Transporter Activity in Drug Development: Current Applications and Future Horizon.内源性生物标志物在药物开发中评估转运体活性的作用扩展：当前应用与未来展望

Pharmaceutics. 2024 Jun 25;16(7):855. doi: 10.3390/pharmaceutics16070855.

Utilising Endogenous Biomarkers in Drug Development to Streamline the Assessment of Drug-Drug Interactions Mediated by Renal Transporters: A Pharmaceutical Industry Perspective.利用药物开发中的内源性生物标志物简化药物 - 药物相互作用的评估：制药行业的视角。

Clin Pharmacokinet. 2024 Jun;63(6):735-749. doi: 10.1007/s40262-024-01385-0. Epub 2024 Jun 13.

Use of a Double-Transfected System to Predict hOCT2/hMATE1-Mediated Renal Drug-Drug Interactions.利用双转染系统预测 hOCT2/hMATE1 介导的肾脏药物相互作用。

Drug Metab Dispos. 2024 Mar 13;52(4):296-304. doi: 10.1124/dmd.123.001567.

Membrane transporters in drug development and as determinants of precision medicine.药物开发中的膜转运体和精准医学的决定因素。

Nat Rev Drug Discov. 2024 Apr;23(4):255-280. doi: 10.1038/s41573-023-00877-1. Epub 2024 Jan 24.

A Literature Review of Changes in Phase II Drug-Metabolizing Enzyme and Drug Transporter Expression during Pregnancy.孕期II期药物代谢酶和药物转运体表达变化的文献综述

Pharmaceutics. 2023 Nov 15;15(11):2624. doi: 10.3390/pharmaceutics15112624.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验